INS and obesity disorder: GLP‐1 receptor agonists (GLP‐1 RAs), such as liraglutide, semaglutide and tirzepatide, were developed to treat obesity as they promote satiety, delay gastric emptying and enhance glucose‐dependent insulin secretion.5